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Abstract 
Background 
PREDICT version 2.0 is increasingly used to estimate prognosis in breast cancer. This study aimed to validate 
this tool in specific prognostic subgroups in the Netherlands.  
Methods 
All operated women with non-metastatic primary invasive breast cancer, diagnosed in 2005, were selected from 
the nationwide Netherlands Cancer Registry. Predicted and observed 5- and 10-year overall survival (OS) were 
compared for the overall cohort, separated by oestrogen receptor (ER) status, and predefined subgroups. A >5% 
difference was considered as clinically relevant. Discriminatory accuracy and goodness-of-fit were determined 
using the area under the receiver operating characteristic curve (AUC) and the Chi2-test. 
Results 
We included 8,834 patients. Discriminatory accuracy for 5-year OS was good (AUC 0.80). For ER+ and ER- 
patients, AUCs were 0.79 and 0.75, respectively. Predicted 5-year OS differed from observed by -1.4% in the 
entire cohort, -0.7% in ER+ and -4.9% in ER- patients. Five-year OS was accurately predicted in all subgroups. 
Discriminatory accuracy for 10-year OS was good (AUC 0.78). For ER+ and ER- patients AUCs were 0.78 and 
0.76, respectively. Predicted 10-year OS differed from observed by -1.0% in the entire cohort, -0.1% in ER+ and -
5.3 in ER- patients. Ten-year OS was overestimated (6.3%) in patients ≥75 years and underestimated (-13.%) in 
T3 tumours and patients treated with both endocrine therapy and chemotherapy (-6.6%). 
Conclusions 
PREDICT predicts OS reliably in most Dutch breast cancer patients, although results for both 5-year and 10-year 
OS should be interpreted carefully in ER- patients. Furthermore, 10-year OS should be interpreted cautiously in 
patients ≥75 years, T3 tumours and in patients considering endocrine therapy and chemotherapy. 
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Introduction 
Adjuvant systemic therapy is shown to reduce recurrence rates in breast cancer patients[1, 2]. In the current era 
of personalised cancer medicine, limiting under- and overtreatment is increasingly important to optimize the 
therapeutic benefit while minimizing short- and long-term side effects of treatment[3]. To personalize breast 
cancer treatment, several prediction tools have been developed including the online tools Adjuvant! Online[4] and 
PREDICT[5]. Adjuvant! Online is developed using the Surveillance, Epidemiology and End-Results (SEER) 
registry and predicts 10-year risks for recurrence, breast cancer specific-mortality and mortality due to other 
causes, including the expected benefit of adjuvant systemic treatments based on patient- and tumour-related 
factors. In the Netherlands, the online prediction tool Adjuvant! Online[4] has been widely used in clinical 
practice[6]. However, Adjuvant! Online has been described to overestimate survival outcomes in several breast 
cancer populations[7-11]. PREDICT was developed using cancer registry data from the United Kingdom (UK) and 
predicts 5-year and 10-year overall survival (OS) for individual breast cancer patients, based on several patient- 
and tumour-related characteristics[5]. It also provides the expected benefits of chemotherapy, endocrine therapy 
and trastuzumab. PREDICT version 1 was released in 2011 and the use of the tool increased steadily until 2016, 
whereafter its use increased substantially following disabling of Adjuvant! Online[12]. PREDICT version 1 has 
been validated on multiple independent case-cohorts from several countries including the UK, Canada, Malaysia 
and the Netherlands[13-18].  
Yet PREDICT has not been validated on the entire Dutch breast cancer population. Moreover, a new version of 
PREDICT, version 2.0, has become available recently[19]. In version 2.0, the model was improved with the 
addition of the options of using the exact tumour size in millimetres, the exact number of positive lymph nodes, 
and the presence of micrometastases. In addition, follow-up was extended.  
This study aimed to validate the online prediction tool PREDICT version 2.0 in a large population-based cohort in 
the Netherlands. Separate analyses were performed to study its validity in specific prognostic subgroups. 
 
Methods 
Design 
In this large historic population-based cohort study, data on patient-, tumour- and treatment-related characteristics 
were obtained from the Netherlands Cancer Registry (NCR). The NCR is hosted by the Netherlands 
Comprehensive Cancer Organisation (IKNL), employing trained registrars to derive data of all patients newly 
diagnosed with cancer directly from patient records. Tumour topography and morphology were coded according 
to the International Classification of Diseases for Oncology, 3rd edition[20]. Staging was coded according to the 
tumour, node and metastasis (TNM) classification system, 6th edition[21]. Additional data on vital status and date 
of death were derived from the Municipal Personal Records database, which was complete until February 2016. 
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Patients 
All women diagnosed with non-metastatic primary invasive breast cancer in 2005 in the Netherlands, who 
received surgery as part of their treatment, were included. Patients who received primary systemic therapy or had 
no pathologically established tumour were excluded. In addition, patients with unknown tumour size, number of 
positive lymph nodes, differentiation grade or oestrogen receptor (ER) status were excluded, since PREDICT 
does not allow missing values for these variables. 
 
Statistical analysis 
The outcomes of interest were 5-year and 10-year OS. The original script of PREDICT was used to calculate the 
expected OS and this was compared with observed OS obtained from the NCR. Comparisons were performed for 
the overall cohort, separated by ER status, and for subgroups based on age, stage, presence of 
micrometastases, grade, HER2 status, type of surgery, use and type of adjuvant systemic therapy and generation 
chemotherapy. A 95% confidence interval (CI) was calculated for the observed numbers. The predicted 
proportions are no real proportions, but reflect the sum of all predictions for each individual. Since uncertainties 
around these predictions were not build into PREDICT, confidence intervals around the prediction estimates and 
differences could not be calculated. To assess goodness-of-fit of the model in each subgroup, observed and 
average predicted events were compared using a Chi2-test. Mode of detection and Ki67 status were set to 
unknown for each patient since these variables were not registered in the NCR. Consequently, PREDICT uses 
the weighted mean coefficient of the unknown variable for these patients. For 2,278 patients who received 
chemotherapy, it was unknown which generation chemotherapy was administered. For this reason, every analysis 
was performed four times. Patients were classified as second generation, third generation, a combination of 
second and third generation (meaning that for these patients the mean coefficient of second generation and third 
generation was used in the predictions) or they were excluded. The analyses were compared, and no significant 
differences in calibration and discrimination between the four methods were observed, both for 5-year and 10-
year OS (Supplementary Figure 1 to 4). Based on these results, it was decided to include all patients with an 
unknown chemotherapy generation and classify them as a combination of second and third generation for all 
further analyses. 
Since PREDICT has been generated on ER+ and ER- patients separately, overall results were stratified by ER 
status, and graphical discrimination and calibration were determined. Discrimination was graphically shown in a 
receiver operating characteristic (ROC) curve. Here, the sensitivity (the proportion of patients who survived and 
were predicted correctly) was plotted against the 1-specificity (the proportion of patients who did not survive but 
were predicted as they would have survived). The discriminatory accuracy was quantified by the area under the 
ROC curve (AUC). An AUC of 0.5 indicates that the model performs as good as flipping a coin, whereas an AUC 
of 1 indicates perfect discrimination. In addition, model calibration was determined by plotting the averages of the 
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observed against the predicted outcomes [with 95% confidence interval (CI)], grouped by quintiles based on the 
predicted estimates. The estimates were subsequently compared with the perfect prediction line (y=x).  An a priori 
assumption was that PREDICT accurately predicted OS whenever the differences between predicted and 
observed outcomes were within a range of 5%, since differences outside of this range were considered as 
clinically relevant. A p-value<0.05 was considered as statistically significant. All statistical analyses were 
performed in STATA version 14.1. 
 
Results 
In total, 10,338 patients with operated, non-metastatic primary invasive breast cancer, diagnosed in 2005 were 
identified. Patients receiving primary systemic therapy (n=529), patients without a pathologically established 
tumour stage (n=2) or unknown tumour size in millimetres (n=332), missing number of positive lymph nodes 
(n=118), unknown differentiation grade (n=418) or ER status (n=105) were excluded, leading to a final study 
population of 8,834 patients (85% of the total population). Most patients presented with T1 (60.4%), N0 stage 
(62.2%), grade II (45.1%), ER positive (82.2%) and HER2 negative disease (69.8%). The majority of the patients 
did not receive adjuvant systemic therapy (61.7%) (Table 1). The median age was 58 years (interquartile range: 
49-69 years). Median follow-up of this population was 10.4 years (interquartile range 9.2-10.7). 
 
Discriminatory accuracy and calibration for 5-year OS 
In the entire Dutch validation population, discriminatory accuracy for 5-year OS was good with an AUC of 0.80. 
Within ER+ and ER- patients separately, the AUCs were 0.79 and 0.75, respectively (Figure 1). The predicted 
number of survivors after 5 years in the entire cohort was 7595.2 (86.0%) compared to 7723 (87.4%) observed 
survivors (Table 1). The difference was -1.4%, which was not significant (p=0.14). In ER+ patients, the difference 
between predicted and observed events was -0.7% (p=0.53). In ER- patients, the difference between predicted 
and observed events was -4.9%, which was statistically significant (p=0.02), but just within the range of 5% (Table 
1). Figure 2 shows the predicted and observed 5-year OS by quintiles of the predicted survival. For the entire 
cohort and for ER+ patients, the predicted and observed 5-year OS do not differ significantly. However, for ER- 
patients, the predicted 5-year OS was significantly lower than the observed 5-year OS, with the largest deviations 
seen in the lowest and highest quintiles (Figure 2). For patients treated with breast-conserving surgery, 5-year OS 
was slightly underestimated with 2.9% (p=0.03), but this was within the range of 5%. For all other predefined 
subgroups no statistically significant differences between predicted and observed events were observed (Table 
1). 
 
Discriminatory accuracy and calibration for 10-year OS 
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In the entire Dutch validation population, discriminatory accuracy for 10-year OS was good with an AUC of 0.78. 
Within ER+ and ER- patients separately, the AUCs were 0.78 and 0.76, respectively (Figure 3). The predicted 
number of survivors after 10 years in the entire cohort was 6404 (72.5%) compared to 6493 (73.5%) observed 
events. The difference was -1.0%, which was not significant (p=0.27). In ER+ patients, the difference between 
predicted and observed events was -0.1% (p=0.92). In ER- patients, the difference between predicted and 
observed events was -5.3%, which was statistically significant (p=0.01). (Table 1). Figure 3 shows the predicted 
and observed 10-year OS by quintiles of the predicted survival. For the entire cohort and for ER+ patients, the 
predicted 5-year OS did not differ from the observed 5-year OS. However, for ER- patients a significant 
underestimation was seen (p=0.01), with the most pronounced deviations in the two highest quintiles. In the 
predefined subgroups, a significant overestimation (6.3%, p<0.01) of 10-year OS was observed in patients ≥75 
years. Ten-year OS was significantly underestimated by PREDICT in T3 tumours (-13%, p<0.01), grade III (-
3.2%, p=0.03), patients treated with breast-conserving surgery (-3.0%, p=0.02), patients treated with 
chemotherapy only (-4.8%, p=0.01, patients treated with both endocrine therapy and chemotherapy (-6.6%), 
p=0.03) and in patients with an unknown generation of chemotherapy (-4.4%, p=0.02). However, the only 
differences outside the range of 5%, were in patients ≥75 years (overestimation), T3 tumours and patients treated 
with both endocrine therapy and chemotherapy (underestimation).  
 
Discussion 
PREDICT version 2.0 accurately predicts 5-year OS in the entire Dutch validation population and in all predefined 
subgroups. Ten-year survival was predicted quite well, although underestimation was observed in ER- patients, 
T3 tumours and patients treated with both endocrine therapy and chemotherapy. In addition, 10-year OS was 
overestimated in patients ≥75 years. Of note, 5-year OS for ER- patients was underestimated (4.9%). Although 
this difference was within the range of 5%, it was statistically significant and became larger when estimating 10-
year OS. 
The finding that 10-year OS was underestimated in ER- patients, but was accurately predicted in ER+ patients is 
in contrast to a previous validation study of PREDICT version 2.0 where slightly better predictions were reported 
for ER- patients than for ER+ patients[19]. A possible explanation for this discrepancy may be the inclusion of 
different populations (UK versus Dutch population). Two previous studies in the Netherlands have validated 
PREDICT version 1.2. The first, only including patients ≥65 years, showed that PREDICT version 1.2 largely 
overestimated 5-year OS in patients ≥85 years, and that 10-year OS was highly overestimated in patients ≥75 
years[17]. The second, only including patients <50 years, showed that PREDICT version 1.2 accurately predicted 
10-year OS in patients <50 years, but that it was underestimated for patients <40 years[18]. Another validation 
study of the 1.2 version in the UK in patients <40 years showed that 10-year OS was accurately predicted, but 
that 5-year OS was highly overestimated with 25%[15]. The updated version 2.0 is described to provide more 
7 
 
accurate predictions in all age groups in three independent validation cohorts, in contrast to version 1.2[14], 
suggesting that the newest version may perform better in all subgroups based on age[19]. Our study confirms this 
for 5-year OS, which was accurately predicted in all subgroups based on age. However, for patients ≥75 years, 
we still found an overestimation for 10-year OS. Of note, this was to a much lesser extent than the previous 
validation study in the Netherlands[17]. The still existing overestimation of 10-year OS in patients ≥75 years may 
partially be explained by the prevalence of comorbidities in older patients. PREDICT gives survival estimates for 
individual patients based on the average comorbidity for women with breast cancer of a similar age[12]. However, 
any increased prevalence of comorbidities or an overrepresentation of older patients in our cohort may have led 
to a lower OS.  
Our findings that PREDICT version 2.0 underestimates 10-year OS in T3 tumours and patients treated with both 
endocrine therapy and chemotherapy may partly be explained by the fact that the PREDICT model has been 
generated on a population diagnosed from 1999 to 2003 in the UK. Our validation population consisted of patients 
diagnosed in 2005, in which differences in OS may partly reflect increased survival over time. Another explanation 
may be the differences in health care provided in the Netherlands and the UK. The large underestimations in 
patients with T3 stage is most likely to be explained by an underrepresentation of this group in the UK 
development population[5], but it may also be caused by differences in treatment strategies or other prognostic 
characteristics differing between our validation population and the development population. Of course, patients 
with T3 stage have a poorer prognosis compared to patients with T1 or T2 stage and have a higher likelihood of 
being treated with adjuvant systemic therapy. Since PREDICT is designed to assist in taking treatment decisions, 
the underestimation of 10-year OS may be therefore of less relevance in this specific patient group as far as 
decision-making concerns. It remains of course a shortage for the prediction of outcome to inform the patients. 
Similarly, for the underestimation of 10-year OS in patients treated with both endocrine therapy and 
chemotherapy, it should be noted that treatment effects cannot be extracted from predictions of the model, since 
the patients included in the validation already received their treatment, independent of the predictions in the 
model.  
The accuracy of a prediction model can be interpreted in different ways. Several studies consider a difference 
between predicted and observed outcomes of less than 2% as accurate[8, 22], while other studies base their 
interpretation on the 95%CI and corresponding p-value[16, 18]. According to the Dutch national guidelines, 
adjuvant systemic therapy is recommended in case of an absolute risk of 10-year breast cancer-related mortality 
of 15% or more. With the 15-year relative mortality reductions described by the EBCTCG ranging between 20 to 
57%[1], the absolute mortality reduction for most patients will be at least 4-5%[23]. A significant difference 
between predicted and observed survival of 5% may therefore systematically be accepted as the threshold to 
alter treatment decisions and was selected as a measure for whether or not differences between predicted and 
observed outcomes are of clinical relevance.  
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Importantly, we should be aware that any inaccurate prediction for a specific subgroup as a whole does not mean 
that this is applicable to every single patient in this subgroup. 
 
Strengths and limitations 
To our knowledge, this is the first population-based study in the Netherlands covering the entire PREDICT target 
population that validates PREDICT version 2.0 in specific prognostic subgroups. The population-based setting 
and the large number of included patients increase the generalisability and reliability of the results.  
A limitation of this study is the absence of knowledge on cause-specific mortality, preventing us from determining 
whether discrepancies are due to breast cancer-specific mortality or other causes of death. Another limitation of 
this study is lacking data on mode of detection and Ki67, which were set to unknown for all patients accordingly. 
Symptomatic cancers are more likely to present with unfavourable tumour characteristics compared to screen-
detected cancers[24]. Thereby, this limitation may partly be neutralised by inclusion of the most important 
prognostic tumour characteristics in the PREDICT model. However, even after correction for these characteristics, 
mode of detection remains associated with survival outcomes[24] and may therefore have affected our results. 
Furthermore, Ki67 has been described to play an important role in breast cancer prognosis[25], and not taking 
Ki67 status into account may have affected the results. However, substantial heterogeneity is observed in the 
methods of Ki67 assessment[26], which may limit its usefulness in determining a patient’s prognosis and may 
explain why it is not routinely used in the Netherlands. 
 
Conclusions 
PREDICT accurately predicts 5-year OS in the overall Dutch validation population, and in all predefined 
subgroups. Although within the range of 5%, 5-year OS for ER- patients should be interpreted with care. 
Furthermore, 10-year OS was overestimated for patients ≥75 years, and underestimated for ER- disease, T3 
tumours and for patients receiving both endocrine therapy and chemotherapy. Given PREDICT’s intentions to 
guide treatment decision-making, PREDICT may serve as a reliable prediction tool for the Dutch breast cancer 
population. However, 5-year OS should be interpreted cautiously in ER- disease, and 10-year OS should be 
interpreted with care in patients ≥75 years, ER- disease, T3 tumours and in patients considering endocrine 
therapy and chemotherapy.  
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Table 1. Observed and predicted 5- and 10-year overall survival by patient-, tumour- and treatment-related characteristics 
  5-year OS 10-year OS 
 N (%) Predicted (%) Observed (%, 
95% CI) 
Difference (%) p-value* Predicted (%)  Observed (%, 
95% CI) 
Difference (%)  p-value* 
Entire cohort 8,834 (100) 7595.2 (86.0) 7723 (87.4) 
(86.7 – 88.1) 
-127.8 (-1.4) 0.14 
 
6404.2 (72.5) 6493 (73.5) 
(72.6 – 74.4) 
-88.8 (-1.0) 0.27 
 
ER status          
Positive 7,263 (82.2) 6466.9 (89.0) 6517 (89.7) 
(89.0 – 90.4) 
-50.1 (-0.7) 0.53 
 
5454.2 (75.1) 5460 (75.2) 
(74.2 – 76.2) 
-5.8 (-0.1) 0.92 
 
Negative 1,571 (17.8) 1128.3 (71.8) 1206 (76.8) 
(74.6 – 78.8) 
-77.5 (-4.9) 0.02 
 
950.0 (60.5 ) 1033 (65.8) 
(63.3 – 68.1) 
-83.0 (-5.3) 0.01 
 
Age           
<40 495 (5.6) 437.5 (88.4) 451 (91.1) 
(88.3 – 93.5) 
-13.5 (-2.7) 0.52 
 
393.3 (79.5) 404 (81.6) 
(77.9 – 84.9) 
-10.7 (-2.2) 0.59 
 
40-49 1,735 (19.6) 1562.7 (90.1) 1602 (92.3) 
(91.0 – 93.5) 
-39.3 (-2.2) 0.32 
 
1413.7 (81.5) 1485 (84.0) 
(83.8 – 87.2) 
-71.3 (-2.6) 0.06 
 
50-64 3,529 (40.0) 3173.0 (90.0) 3247 (92.0) 
(91.1 – 92.9) 
-74.0 (-2.1) 0.19 
 
2826.8 (80.1) 2918 (82.7) 
(81.4 – 83.9) 
-91.2 (-2.6) 0.09 
 
65-74 1,869  (21.2) 1606.5 (6.0) 1644 (88.0) 
(86.4 – 89.4) 
-37.5 (-2.0) 0.35 
 
1302.1 (69.7) 1321 (70.7) 
(68.6 – 71.7) 
-18.9 (-1.0) 0.60 
 
≥75 1,206 (13.7) 815.5 (67.6) 779 (64.6) 
(61.8 – 67.3) 
36.5 (3.0) 0.20 
 
468.2 (38.8) 392 (32.5) 
(29.9 – 35.2) 
76.2 (6.3) 0.00 
 
T stage          
1 5,331 (60.4) 4822.1 (90.5) 4912 (92.1) 
(91.4 – 92.8) 
-89.9 (-1.7) 
 
0.19 
 
4233.0 (79.4) 4280 (80.3) 
(79.2 – 81.4) 
-47.0 (-0.9) 0.47 
 
2 3,176 (36.0) 2563.9 (80.7) 2592 (81.6) 
(80.3 – 83.0) 
-28.1 (-0.9) 0.58 
 
2035.7 (64.1) 2058 (64.8) 
(63.1 – 66.5) 
-22.3 (-0.7) 0.62 
 
3 230 (2.6) 145.8 (63.4) 164 (71.3) 
(65.5 – 77.2) 
-18.2 (-7.9) 0.13 
 
95.2 (41.4) 125 (54.3) 
(47.7 – 60.9)  
-29.8 (-13.0) 0.00 
 
4 97 (1.1) 63.4 (65.4) 55 (56.7) 
(46.3 – 66.7) 
8.4 (8.7) 0.29 
 
40.2 (41.5) 30 (30.9) 
(21.7 – 40.1)  
10.2 (10.6) 0.11 
 
N stage          
0 5,496 (62.2) 4908.9 (89.3) 4994 (90.9) 
(90.1 – 91.6) 
 -85.1 (-1.5) 0.23 
 
4257.0 (77.5) 4290 (78.1) 
(77.0 – 79.2) 
-33.0 (-0.6) 0.61 
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1 2,408 (27.3) 2057.5 (85.4) 2078 (86.3) 
(84.9 – 87.7) 
 -20.5 (-0.8) 0.65 
 
1715.6 (71.2) 1723 (71.6) 
(69.8 – 73.4) 
-7.4 (-0.3) 0.86 
 
2 604 (6.8) 439.2 (72.7) 455 (75.3) 
(71.9 – 78.8) 
-15.8 (-2.6) 0.45 
 
320.1 (53.0) 349 (57.8) 
(53.9 – 61.7) 
-28.9 (-4.8) 0.11 
 
3 326 (3.7) 189.6 (58.1) 196 (60.1) 
(54.8 – 65.4) 
-6.4 (-2.0) 0.64 
 
111.4 (34.2) 131 (40.2) 
(34.9 – 45.5) 
-19.6 (-6.0) 0.06 
 
Presence of 
micrometastases 
    
 
    
No 8,321 (94.2) 7130.6 (85.7) 7251 (87.1) 
(86.4 – 87.9) 
-120.4 (-1.4) 0.15 
 
5995.5 (72.1) 6090 (73.2) 
(72.2 – 71.1) 
-94.5 (-1.1) 0.22 
 
Yes 513 (5.8) 464.5 (90.6) 472 (92.0) 
(89.7 – 94.4) 
-7.5 (-1.5) 0.73 
 
408.7 (79.7) 403 (78.6) 
(75.0 – 82.1) 
5.7 (1.1) 0.78 
 
Grade          
I 1,992 (22.6) 1841.2 (92.4) 1856 (93.2) 
(92.1 – 94.3) 
-14.8 (-0.7) 0.73 
 
1632.5 (82.0) 1620 (81.3) 
(79.6 – 83.0) 
12.5 (0.6) 0.75 
 
II 3,983 (45.1) 3507.5 (88.1) 3546 (89.0) 
(88.1 – 90.0) 
51.5 (-1.0) 0.38 
 
2968.3 (74.5) 2979 (74.8) 
(73.4 – 76.1) 
-10.7 (-0.3) 0.84 
 
III 2,859 (32.4) 2246.5 (78.6) 2321 (81.2) 
(79.7 – 82.6) 
-74.5 (-2.6) 0.12 
 
1803.3 (63.1) 1894 (66.2) 
(64.5 – 68.0) 
-90.7 (-3.2) 0.03 
 
HER2 status          
Negative 6,169 (69.8) 5350.0 (86.7 ) 5433 (88.1) 
(87.3 – 88.9) 
-83.0 (-1.3) 0.26 
 
4524.0 (73.3 ) 4580 (74.2) 
(73.2 – 75.3) 
-56.0 (-0.9) 0.41 
 
Positive 1,149 (13.0) 950.3 (82.7) 1001 (87.1) 
(85.2 – 89.1) 
-50.7 (-4.4) 0.10 
 
804.5 (70.0) 853 (74.2) 
(71.7 – 76.8) 
-48.5 (-4.2) 0.09 
 
Unknown 1,516 (17.2) 1294.8 (85.4) 1289 (85.0) 
(83.2 – 86.8) 
5.8 (0.4) 0.86 
 
1075.6 (71.0) 1060 (69.9) 
(67.6 – 72.2) 
15.6 (1.0) 0.63 
 
Type of surgery          
Breast-conserving surgery  5,070 (57.4) 4563.0 (90.0) 4709 (92.9) 
(92.2 – 93.6) 
-146.0 (-2.9) 0.03 
 
4008.5 (79.1) 4162 (82.1) 
(81.0 – 83.1) 
-153.5 (-3.0) 0.02 
 
Mastectomy 3,764 (42.6) 3032.2 (80.1) 3014 (80.1) 
(78.8 – 81.4) 
18.2 (0.5) 0.74 
 
2395.7 (63.6) 2331 (61.9) 
(60.4 – 63.5) 
64.7 (1.7) 0.19 
 
Adjuvant systemic 
therapy 
  
 
      
No 5,454 (61.7) 4730.9 (86.7) 4748 (87.1) -17.2 (-0.3) 0.81 3952.2 (72.5) 3888 (71.3) 64.2 (1.1) 0.31 
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(86.2 – 87.9)  (70.1 – 72.5)  
Only endocrine therapy 214 (2.4) 172.4 (80.6) 165 (77.1) 
(71.5 – 82.7) 
7.4 (3.5) 0.57 
 
126.6 (59.2) 112 (52.3) 
(45.6 – 59.0) 
14.6 (6.8) 0.19 
 
Only chemotherapy 2,306 (26.1) 1904.4 (82.6) 1985 (86.1) 
(84.7 – 87.5) 
-80.6 (-3.5) 0.06 
 
1632.3 (70.8) 1743 (75.6) 
(73.8 – 77.3) 
-110.7 (-4.8) 0.01 
 
Both 860 (9.7) 787.5 (91.6) 825 (95.9) 
(94.6 – 97.3) 
-37.5 (-4.4) 0.18 
 
693.1 (80.6) 750 (87.2) 
(85.0 – 89.4) 
-56.9 (-6.6) 0.03 
 
Generation chemotherapy          
No chemotherapy 5,668 (64.2) 4903.3 (86.5) 4913 (86.7) 
(85.8 – 87.6) 
-9.7 (-0.2) 0.89 
 
4078.8 (72.0 ) 4000 (70.6) 
(69.4 – 71.8) 
78.8 (1.4) 0.22 
 
Generation 2 615 (7.0) 555.1 (90.3) 585 (95.1) 
(93.4 – 96.8) 
-29.9 (-4.9) 0.20 
 
491.3 (79.9) 532 (86.5) 
(83.8 – 89.2) 
-40.7 (-6.6) 0.07 
 
Generation 3 416 (4.7) 355.7 (85.5) 378 (90.9) 
(88.1 – 93.6) 
-22.3 (-5.3) 0.24 
 
311.0 (74.8) 344 (82.7) 
(79.1 – 86.3) 
-33.0 (-7.9) 0.06 
 
Generation unknown 2,135 (24.2) 1781.0 (83.4) 1847 (86.5) 
(85.1 – 88.0) 
-66.0 (-3.1) 0.12 
 
1523.1 (71.3) 1617 (75.7) 
(73.9 – 77.6) 
-93.9 (-4.4) 0.02 
 
Abbreviations: N = total number, SE = standard error, CI = confidence interval, ER = oestrogen receptor, HER2 = human epidermal growth factor receptor.  
*The p-value was calculated by using a Chi2-test. P-values indicated in bold are considered as statistically significant (p<0.05) 
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Figure 1. Discriminatory accuracy of 5-year overall survival for the entire cohort, ER+ patients and ER- patients. Abbreviations: ROC = receiver operating characteristic 
curve, ER = oestrogen receptor 
 
16 
 
 
Figure 2. Observed and predicted 5-year overall survival for the entire cohort, ER+ patients and ER- patients. Abbreviations: CI = confidence interval, ER = oestrogen 
receptor 
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Figure 3. Discriminatory accuracy of 10-year overall survival for the entire cohort, ER+ patients and ER- patients. Abbreviations: ROC = receiver operating 
characteristic curve, ER = oestrogen receptor 
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Figure 4. Observed and predicted 10-year overall survival for the entire cohort, ER+ patients and ER- patients. Abbreviations: CI = confidence interval, ER = oestrogen 
receptor 
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